Bristol-Myers Squibb joined the urology treatment developer's investors in a round led by Yonghua Capital.

Existing investors Chiesi Ventures and Li-Cor Biosciences came back for the cancer treatment developer's Lundbeckfonden Ventures-led series C.

Bigfinite has picked up funding from industrial process manufacturer Krohne as it bids to commercialise its pharmaceutical information platform.

FLX Bio has secured $60m in a series C round featuring GV and existing investor Celgene to take its total funding to almost $140m.

The healthcare management platform has secured $23m of a planned $28m, after raising $20m in a GV-backed round in January.

The pair will anchor Bright Angel Therapeutics as founding shareholders, providing resources to drive an antifungal enhancement program advancing discoveries made at MIT and University of Toronto.

Corporates Varner and Gjensidige are among the limited partners for Hadean Ventures' first fund, which will back European life sciences startups.